文献速递系统性红斑狼疮

肠溶霉酚酸钠与硫唑嘌呤治疗活动性系统性红斑狼疮的随机临床试验

Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial.
PubMed 文献 · Ann Rheum Dis · 2017-04-27

这项多中心、24个月、优效性、开放标签随机对照试验纳入240例活动性SLE患者,比较肠溶霉酚酸钠(EC-MPS)与硫唑嘌呤(AZA)的疗效与安全性。结果显示EC-MPS组在3个月和24个月临床缓解率均更高,且至临床缓解时间更短、BILAG复发率更低;两组不良事件相似,但AZA组白细胞减少更常见。

要点

  • EC-MPS组24个月临床缓解率71.2%,显著高于AZA组48.3%(治疗差异22.9,CI 10.4至34.4,p<0.001)。
  • EC-MPS组至临床缓解时间更短(HR 1.43;95%CI 1.07至1.91;p=0.017)。
  • AZA组BILAG A/B复发和B复发更频繁,EC-MPS在预防复发方面更优。

核心结论

  • 在活动性SLE患者中,EC-MPS在诱导和维持临床缓解及预防复发方面优于AZA。

研究设计与样本

  • 多中心、24个月、优效性、开放标签随机对照试验(NCT01112215),共240例患者(每组120例),分别接受EC-MPS(目标剂量1440 mg/天)或AZA(目标剂量2 mg/kg/天),并联合泼尼松和/或抗疟药。

主要发现

  • 3个月临床缓解率(临床SLEDAI=0)EC-MPS组32.5% vs AZA组19.2%(治疗差异13.3,CI 2.3至24,p=0.034)。
  • 24个月临床缓解率EC-MPS组71.2% vs AZA组48.3%(治疗差异22.9,CI 10.4至34.4,p<0.001)。
  • 至临床缓解时间EC-MPS更优(HR 1.43;95%CI 1.07至1.91;p=0.017)。
  • BILAG A/B复发率AZA组71.7% vs EC-MPS组50%(p=0.001),BILAG B复发率AZA组21.67% vs EC-MPS组8.3%(p=0.004)。
  • 至首次BILAG A/B复发时间EC-MPS更优(HR 1.81;95%CI 1.3至2.56;p=0.0004),至BILAG A复发时间EC-MPS更优(HR 2.84;95%CI 1.37至5.89;p=0.003)。

关键数值与推荐

  • 主要终点为3个月和24个月时达到临床缓解(基于SLEDAI-2K和BILAG评估)的患者比例。
  • EC-MPS目标剂量1440 mg/天,AZA目标剂量2 mg/kg/天。
  • 不良事件两组相似,但白细胞减少在AZA组更常见。

临床怎么用

  • 对于活动性SLE患者,EC-MPS可作为优于AZA的免疫抑制剂选择,尤其在提高缓解率和减少复发方面。
  • 使用AZA时需更注意监测白细胞减少。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS) versus azathioprine (AZA) in patients with active systemic lupus erythematosus (SLE) disease. METHODS: A multicentre, 24-month, superiority, open-label, randomised controlled trial (NCT01112215) was conducted with 240 patients (120 per arm) receiving either EC-MPS (target dose: 1440 mg/day) or AZA (target dose: 2 mg/kg/day) in addition to prednisone and/or antimalarials. The primary endpoint was the proportion of patients achieving clinical remission, assessed by SLE Disease Activity Index 2000 (SLEDAI-2K) and British Isles Lupus Assessment Group (BILAG), at 3 and 24 months. Secondary endpoints included time to clinical remission, BILAG A and B flare rates, time to flare, corticosteroid reduction and adverse events (AEs). RESULTS: Proportion of patients achieving clinical remission (clinical SLEDAI=0) was higher in the EC-MPS group at 3 (32.5% vs 19.2%; treatment difference, 13.3 (CI 2.3 to 24), p=0.034) and 24 months (71.2% vs 48.3%; treatment difference, 22.9 (CI 10.4 to 34.4), p<0.001). EC-MPS was superior with respect to time to clinical remission (HR 1.43; 95% CI 1.07 to 1.91; p=0.017). BILAG A/B and B flares occurred more frequently in the AZA group (71.7% vs 50%, p=0.001 and 21.67% vs 8.3%, p=0.004, respectively). EC-MPS was superior with respect to time to first BILAG A/B (HR 1.81; 95% CI 1.3 to 2.56; p=0.0004) and BILAG A flare (HR 2.84; 95% CI 1.37 to 5.89; p=0.003). AEs were similar in both groups except for leucopenia that occurred more frequently with AZA. CONCLUSIONS: EC-MPS was superior to AZA in treating SLE and preventing further relapses. TRIAL REGISTRATION NUMBER: NCT01112215; Results.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, et al. Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. Ann Rheum Dis. 2017. PMID: 28450313. doi:10.1136/annrheumdis-2016-210882

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。